The videogame retailer’s shares jumped following the latest cryptic post from influential trader Keith Gill, aka “Roaring ...
Wedbush raised their Q1 2025 earnings estimates for Keros Therapeutics in a report released on Tuesday, December 3rd. Wedbush ...
Dan Ives, Wedbush global head of technology research, joins 'Closing Bell: Overtime' to discuss Salesforce after the ...
While retail investors might base their trades on memes posted by Roaring Kitty, a leading Wall Street analyst is warning ...
What makes that call particularly surprising is that most pundits are still skeptical about Palantir. Among the 20 analysts ...
Musk reacted on his X social media platform to the ruling on Monday by Court of Chancery Judge Kathleen McCormick.
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...
In a report released today, Daniel Ives from Wedbush maintained a Buy rating on Salesforce (CRM – Research Report), with a price target of ...
Wedbush analyst Daniel Ives raised the firm’s price target on Salesforce (CRM) to $425 from $375 and keeps an Outperform rating on the shares. The firm notes the company delivered its Q3 results ...
https://www.tipranks.com/news/the-fly/snap-price-target-raised-to-13-from-11-at-citi As previously reported, Wedbush upgraded Pinterest (PINS) to Outperform from ...
Wedbush upgraded HomeStreet (HMST) to Outperform from Neutral with an unchanged price target of $12. The shares sold off heavily last week after it was announced that FirstSun Capital’s (FSUN ...
Tesla (TSLA, $845.00) stock has the potential to reach $950 per share, says Wedbush analyst Daniel Ives. But he still doesn’t think you should buy it. The 11 Best Growth Stocks to Buy for 2021 ...